The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Open accessAbstract
BACKGROUND: Influenza A viruses cause occasional pandemics and frequent epidemics. Licensed influenza vaccines that induce high antibody titers to the highly polymorphic viral surface antigen hemagglutinin must be re-formulated and readministered annually. A vaccine providing protective immunity to the highly conserved internal antigens could provide longer-lasting protection against multiple influenza subtypes. METHODS: We prepared a Modified Vaccinia virus Ankara (MVA) vector encoding nucleoprotein and matrix protein 1 (MVA-NP+M1) and conducted a phase I clinical trial in healthy adults. RESULTS: The vaccine was generally safe and well tolerated, with significantly fewer local side effects after intramuscular rather than intradermal administration. Systemic side effects increased at the higher dose in both frequency and severity, with 5 out of 8 volunteers experiencing severe nausea/vomiting, malaise, or rigors. Ex vivo T-cell responses to NP and M1 measured by IFN-γ ELISPOT assay were significantly increased after vaccination (prevaccination median of 123 spot-forming units/million peripheral blood mononuclear cells, postvaccination peak response median 339, 443, and 1443 in low-dose intradermal, low-dose intramuscular, and high-dose intramuscular groups, respectively), and the majority of the antigen-specific T cells were CD8(+). CONCLUSIONS: We conclude that the vaccine was both safe and remarkably immunogenic, leading to frequencies of responding T cells that appear to be much higher than those induced by any other influenza vaccination approach. Further studies will be required to find the optimum dose and to assess whether the increased T-cell response to conserved influenza proteins results in protection from influenza disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytotoxic T-Cell Immunity to Influenza
McMichael, A. J., Gotch, F. M., Noble, G. R., & Beare, P. A. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307073090103 · Cited by 927
McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A., & Hill, A. V. S. (2004) · Nature Medicine · doi:10.1038/nm1128 · Cited by 570
Self-citationLee, L. Y.-H., Ha, D. L. A., Simmons, C., de Jong, M. D., Chau, N. V. V., Schumacher, R., Peng, Y. C., McMichael, A. J., Farrar, J. J., Smith, G. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32460 · Cited by 422
He, X.-S., Holmes, T. H., Zhang, C., Mahmood, K., Kemble, G. W., Lewis, D. B., Dekker, C. L., Greenberg, H. B., & Arvin, A. M. (2006) · Journal of Virology · doi:10.1128/jvi.01460-06 · Cited by 321
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
Epstein, S. L., Kong, W.-P., Misplon, J. A., Lo, C.-Y., Tumpey, T. M., Xu, L., & Nabel, G. J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.047 · Cited by 285
Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S., Tavarini, S., Sammicheli, C., Hilbert, A. K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813390106 · Cited by 261
Priddy, F. H., Brown, D., Kublin, J., Monahan, K., Wright, D. P., Lalezari, J., Santiago, S., Marmor, M., Lally, M., Novak, R. M., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587993 · Cited by 253
de Jong, J. C., Beyer, W. E. P., Palache, A. M., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200005)61:1<94::aid-jmv15>3.0.co;2-c · Cited by 230
Beveridge, N. E. R., Price, D. A., Casazza, J. P., Pathan, A. A., Sander, C. R., Asher, T. E., Ambrozak, D. R., Precopio, M. L., Scheinberg, P., Alder, N. C., et al. (2007) · European Journal of Immunology · doi:10.1002/eji.200737504 · Cited by 224
Self-citationEbels, T., & Homan Van Der Heide, J. N. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90264-1 · Cited by 188
Research works printed but not linked: 10
- 2008, MMWR. Morbidity and mortality weekly report, 57, 393
- Breathnach, 2006, Vaccine, 24, 1180, 10.1016/j.vaccine.2005.08.091 · doi:10.1016/j.vaccine.2005.08.091
- Donnelly, 1997, Vaccine, 15, 865, 10.1016/S0264-410X(96)00268-X · doi:10.1016/s0264-410x(96)00268-x
- 2006, Clinical Infectious Diseases, 42, 1102, 10.1086/501459 · doi:10.1086/501459
- Dorrell, 2005, AIDS (London, England), 19, 1321, 10.1097/01.aids.0000180104.65640.16 · doi:10.1097/01.aids.0000180104.65640.16
- Vuola, 2005, The Journal of Immunology, 174, 449, 10.4049/jimmunol.174.1.449 · doi:10.4049/jimmunol.174.1.449
- Gilbert, 2002, Vaccine, 20, 1039, 10.1016/S0264-410X(01)00450-9 · doi:10.1016/s0264-410x(01)00450-9
- 2009, Vaccine, 28, 21, 10.1016/j.vaccine.2009.09.132 · doi:10.1016/j.vaccine.2009.09.132
- Webster, 2006, Vaccine, 24, 3026, 10.1016/j.vaccine.2005.10.058 · doi:10.1016/j.vaccine.2005.10.058
- Whelan, 2009, 4, e5934, 10.1371/journal.pone.0005934 · doi:10.1371/journal.pone.0005934
Cited by
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Havey, T. C., Fowler, R. A., & Daneman, N. (2011) · Critical Care · doi:10.1186/cc10545 · Cited by 187
Baby, N., Faust, A. C., Smith, T., Sheperd, L. A., Knoll, L., & Goodman, E. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02432-16 · Cited by 94
The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia
McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit560 · Cited by 90
Immunosenescence and vaccine failure in the elderly: strategies for improving response
Boraschi, D., & Italiani, P. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.06.006 · Cited by 86
Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection
Merani, S., Pawelec, G., Kuchel, G. A., & McElhaney, J. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00784 · Cited by 74
Metadata
- Authors
- Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C., Lambe, T., Fletcher, H. A., Hill, A. V. S., & Gilbert, S. C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-01
- Volume
- 52
- Issue
- 1
- Pages
- 1-7
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2132287875
- Cited by
- 384
- References
- 16
- FWCI
- 26.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. https://app.cochat.ai/papers/10.1093/cid/ciq015
- The paper
- Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C., Lambe, T., Fletcher, H. A., Hill, A. V. S., & Gilbert, S. C. (2011). Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciq015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
